Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
P/B ratio for Ampio Pharmaceuticals, Inc. (AMPE)
P/B ratio as of 2023: 0.49
According to Ampio Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.49. At the end of 2022 the company had a P/B ratio of 0.29.
P/B ratio history for Ampio Pharmaceuticals, Inc. from 2006 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.49 |
| 2022 | 0.29 |
| 2021 | 4.16 |
| 2020 | 15.69 |
| 2019 | 12.80 |
| 2018 | 8.25 |
| 2017 | -7.75 |
| 2016 | 7.28 |
| 2015 | 4.92 |
| 2014 | 2.61 |
| 2013 | 8.25 |
| 2012 | 5.12 |
| 2011 | 6.25 |
| 2010 | -10.52 |
| 2009 | -740.55 |
| 2008 | -1483.68 |
| 2007 | -5431.03 |
| 2006 | 3252.00 |